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Germany as well as their spatial distribution, accompanied by their short description. 
key worDS: biotechnology, Germany, regions, clusters, economic geography
Sławomir Dorocki, Institute of Geography, Pedagogical University of Cracow, Podchorążych 2, 30-084 Kraków, Poland; e-mail: 
sdorocki@up.krakow.pl
Introduction 
Nowadays, it is assumed that regional eco-
nomic development is closely related to the 
development of innovation and technological 
progress occurring in a region. Innovation and 
innovation-related economic competitiveness of 
local administrative units at all levels is predom-
inantly dependent on human capital (Borowiec 
2008; Chojnicki, Czyż 2006, 2008; Karlsson, Börje 
2008; Borowiec, Dorocki, Jenner 2009; Borowiec, 
Dorocki 2011). For this reason, this capital is 
highly trained personnel, including academics 
(research staff), highly qualified specialists and 
lower-level staff working in high-tech economic 
sectors (Kilar 2008). It applies both to their edu-
cation and skills and their effort to improve their 
qualifications continuously. The so-called “cre-
ative class” is another condition which guaran-
tees the development of innovative sectors. The 
term also applies to the open attitude the society 
adopts towards transformations and progress 
and the place of creative individuals in the soci-
ety (Stryjakiewicz 2008; Klincewicz 2012). In this 
context, the culture of social relations is a factor 
affecting the development of innovation in an 
area. The attitude of society towards science and 
progress is particularly important in the case of 
authorities and functionaries and their actions, 
both in the financial and legislative aspects. In 
the context of the above-mentioned terms and 
conditions for the development of a modern 
economy, the best conditions for innovation 
growth are offered by cities, in particular by large 
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agglomerations and metropolises (Stryjakiewicz 
2009). This is due to economic aspects (such as 
economic advancement, infrastructure, accessi-
bility of new high-tech solutions and knowledge, 
the economic structure) as well as social aspects 
(such as education, business traditions, and the 
demographic structure). Also, urban centres are 
migratory goals for a large part of the creative 
class (winiarczyk-Raźniak, Raźniak 2012; Gałka, 
Dorocki 2013).
In addition, an innovative economy is reflected 
by the type of growing businesses and the R&D 
base. In the industrialisation period, which has 
come to an end, science, and specifically chem-
istry and physics as well as traditional industry 
related to these sciences, played the key role in 
the economic growth. The end of the 20th century 
brought the dominance of mathematical sciences 
(including applied mathematics) and IT as well as 
the electronic industry (the IT revolution) (Kilar 
2009). At present, biotechnology is considered 
one of the most important branches of science. 
After a period of IT prevalence, biotechnology is 
now being perceived as the most important and 
fastest growing high-tech economic sector (Bauer 
1995; Kelly 2004). For this reason, biotechnology 
represents a material factor of social and eco-
nomic development and of processes involved 
in creating a knowledge-based economy (Zioło 
2006, 2008; Dorocki, Jastrzębski 2012; Pugatch et 
al. 2012). The importance of biotechnology in de-
veloping a knowledge-based economy is related 
to its core features: innovation, versatile applica-
bility, and generating the progress of other basic 
sciences. The increasing role of biotechnology is 
also related to the growth in population number 
and a possible food crisis in poorly developed 
regions, the ageing of society occurring in de-
veloped countries, and scientific and technolog-
ical progress. Biotechnology significantly breaks 
off connections with traditional (hard) business 
location factors, making its development de-
pendent on soft factors, such as largely human 
capital and access to new technologies (infor-
mation, knowledge). This is proved by the fact 
that in biotech companies the share of employees 
having the academic title of a doctor is twice or 
three times higher than in other companies of the 
R&D sector (Beuzekom, Arundel 2009). Another 
important factor stimulating the development 
of biotechnology is transfer of knowledge and a 
dense institutional network characteristic of ur-
banised areas (agglomerations). Spatial concen-
trations of industry and the biotechnology sector 
allow strong relations to grow between economic 
and scientific entities/units and facilitate an ex-
change of mutually complementary knowledge 
(Corolleur et al. 2003; Sytch, Bubenzer 2008; Aha-
ronson et al. 2008; Lecocq at al 2010; Béliveau et 
al. 2011; Domański 2000; Klasik 2009; Chojnicki, 
Czyż 2008; Markowski 2008; Delerue, Lejeune 
2008; Goldberg et al. 2008). The above shows that 
biotech companies grow mainly in the proximity 
of world-class universities which provide them 
with access to highly qualified work force and re-
search infrastructure (Zucker et al. 1989; Stuart, 
Sorenson 2003). Still, the development involves 
high investment risk caused by rapid technolog-
ical changes (Baum, Silverman 2004) and a long 
period needed to market a product.
Contemporary biotechnology processes are 
applied in many industrial sectors and success-
fully compete with traditional methods. Glob-
ally, they are broadly applied in such sectors as 
the chemical industry, pharmaceutical (medi-
cal) industry, pulp and paper industry, textile, 
leather, food processing industries, and the en-
ergy sector. The main fields of activity of the bi-
otechnology sector are: production of starter cul-
tures in the food industry, production of GMO, 
the pharmaceutical sector (production of new 
drugs, vaccines, diagnostic means), the detergent 
and bioremediation sector, biotechnology in the 
farming sector for non-food purposes, and forest-
ry (Dorocki, Brzegowy 2014).
On the basis of the above premises, this ar-
ticle is devoted to analysing the distribution of 
biotechnology centres in Germany. The choice of 
Germany as the field for this study was prompt-
ed by the dominance of Germany on the Europe-
an biotechnological market and is an example of 
an achievement of a regional policy aimed at ac-
tivating local business and academic communi-
ties and connecting the scientific and the business 
zone. These actions were to bring about the de-
velopment of biotech production clusters, which 
Germany considers its regional development in-
strument. Both R&D centres and biotech industry 
plants were taken into account when analysing 
the distribution of biotechnology centres. This 
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article seeks to confirm the spatial compatibility 
of location of both types of institutions and their 
concentration. The analysis is based on data pub-
lished in specialist Internet information services 
as well as in sectoral reports and studies.
Biotechnology around the world
Because of its interdisciplinary nature and 
links with other industries, it is difficult to come 
up with one clear and unequivocal definition of 
the biotechnology sector (Dawidko 2012). This 
author defines biotechnology as the application 
of technological processes which, using living or-
ganisms or their components, produce or modify 
products for specific use. Therefore, biotechnol-
ogy is an interdisciplinary science which inte-
grates natural sciences and engineering.
In Western Europe the biotechnology in-
dustry began developing in large corporations 
in the 1980s. But it was only the late 1990s that 
saw rapid growth of the sector parallel to the 
increasing share of small and medium-sized en-
terprises (SMEs). As early as 2001, the number 
of European SMEs in the biotechnology sector 
increased to 1,570, as against 1,273 operating in 
the USA (Life sciences and biotechnology 2002). 
However, the European biotechnology industry 
continues to fall behind that in the USA. In gen-
eral, the US sector has a much better working net-
work of scientists, entrepreneurs, managers and 
investors, facilitating a rapid flow of information 
both inside companies and institutions and be-
tween them (Casper, Murray 2005; Casper 2009). 
Additionally, the development of the biotechnol-
ogy sector is stimulated by cultural and ‘person-
al’ aspects. Cultural aspects involve the position 
adopted by the authorities and society on un-
dertaking ‘morally sensitive’ scientific activities, 
which is particularly important in the case of in-
itiatives related to genetic modifications, etc. As 
for personal factors, it is believed that in the case 
of human capital in the biotechnology sector, the 
flow of knowledge, in spite of seemingly high 
professional mobility, remains excessively lim-
ited to the spatially concentrated labour market 
(tacit knowledge) (Saxenian 1999; Saxenian et al. 
2003; Dahl, Sorenson 2007). Research also shows 
that R&D personnel tends to choose employers 
locally, which may be related to the personal fac-
tor too (Stryjakiewicz 2008) or to scientific activi-
ty (e.g. their intention to continue their academic 
and research career at universities). The main dif-
ference between the development of the biotech-
nology sector in Europe and the USA probably 
stems from the fact that in the latter the sector 
is growing thanks to businessmen investing in 
science and research, while in Europe the devel-
opment is largely based on using the scientific 
potential (research of R&D centres) of private 
companies or spin-offs linked to scientific cen-
tres (Rothaermel, Deeds 2004; Ukropcova, Stur-
dik 2009). Public institutions in Europe initiate 
the development of the biotechnology industry, 
as demonstrated by the fact that in Germany, a 
country that is a European biotech giant, nearly 
75% of biotechnology companies came to life on 
the basis of research projects financed from pub-
lic funds (Müller 2001). Also nearly 60% of bio-
technology patents were patented by universities 
(wolf et al. 2010).
Globally, the USA reports the highest number 
of biotech companies. According to the OECD, in 
2011 their number reached 7,900, i.e. about 41.6% 
of the global number of such entities (Fig. 1). Ad-
vanced West European countries: Spain, France, 
Germany and the UK, followed in the ranking, 
accounting together with Australia and Japan for 
nearly 40% of biotech companies. In general, the 
biotechnology industry grew predominantly in 
the USA and in developed West European and 
Asian countries. Mexico is the only exception 
among biotechnology leaders. Its high position 
in the ranking is due to the stimulation of the 
development of the biotechnology sector by the 
state and collaboration with the USA, predomi-
nantly in developing GMO (Possani 2003; wój-
towicz, Dorocki 2014). worth noting is that in 
the above-mentioned countries the share of ded-
icated biotech firms which devote at least 75% of 
their production of goods and services, or R&D, 
to biotechnology, is quite insignificant. The high-
est share of such companies (more than 80%) was 
reported for Israel, Ireland, Slovakia and Ger-
many, while in Spain or the Netherlands they 
represent approx. 25% of all biotech companies. 
Irrespective of the data base selected, the biotech-
nological domination of the USA and the EU is 
confirmed (Dorocki, Borowiec, Boguś 2013). 
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Also in terms of biotechnology development, 
the USA is the world leader and, between 2009 
and 2011, submitted nearly 39% of all PCT bio-
technological patents. Japan comes second in 
the ranking, boasting a 12% share in the pool of 
global biotechnological patents. Germany is the 
European leader of the ranking boasting a 7% 
share in PCT applications. The dominance of 
the USA and Western Europe in biotechnologi-
cal patent applications has been undermined by 
Canada, China, Korea, India, Israel and East Eu-
ropean countries (Fig. 2). The process is similar 
when considering the geographical location of 
entities owning patents. The share of the USA as 
the owner of biotechnological patents submitted 
between 1998 and 2001 was steadily going down 
from 56% to 40%. A similar process was observed 
in Germany and other West European countries, 
while Japan and South Korea reported the high-
est growth in this respect. These changes are par-
ticularly important when it comes to the protec-
tion of intellectual property rights. This is mainly 
related to the commercialisation of research, 
which typically requires long completion dates 
as a result of difficulties in raising venture capital 
and attracting investors, as it is assumed that lab 
research is successful and ends with launching a 
new product on the market in 1 out of 500 cases 
(Adelberger 1999). The importance of patent pro-
tection is emphasised by the fact that, according 
to European experts, patent legislation is large-
ly responsible for differences in biotechnology 
advancement between North America and the 
EU (Overwalle 2010). Also many scientific insti-
tutions (e.g. universities) so far have not taken 
commercial requirements into account and force 
scientists to publish their research results before 
processes related to their legal protection and fi-
nancing have been completed. The distribution 
of biotechnological patent applications not only 
indicates the location of scientific activities in the 
sector, but also forms the basis for developing bi-
otech companies in a region.
Similarly, in the case of the most scientifically 
advanced white technology related to the medi-
cal application of biotechnology, Asian countries 
Fig. 1. Number of biotech companies in selected countries as per cent of the total, 2013
Source: own calculations based on OECD data
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including China, Taiwan and Korea dominate 
globally in terms of the number of clinical re-
searches (Fig. 3). It is connected with technologi-
cal and scientific progress of areas considered pe-
ripheral so far and an increasing outsourcing of 
research (Higgins, Rodrigues 2006; Howells et al. 
2008). This applies mainly to relocating cost-gen-
erating stages of the research process (e.g. clini-
cal research) to lower-cost countries (e.g. China, 
Poland, India). These transformations are par-
ticularly notable in Eastern Europe and Asia. Be-
cause of its specificity, nowadays biotechnology 
is developing not only in the traditional econom-
ic and scientific centres of advanced states, but 
also in peripheral and farming regions of devel-
oping countries (Dorocki, Borowiec, Boguś 2013).
Biotechnology in Germany
The German biotechnological industry began 
to develop in 1970. The authorities recognised bi-
otechnology as a sector in the technological and 
economic development of the country, which af-
fected financing its development. Unfortunately, 
due to legal impediments and a strong political 
pressure from the ruling parties, Germany was 
falling well behind the global leaders. The first 
action taken in 1978 by the authorities in sup-
port of the sector was to adopt guidelines for bi-
otechnology prepared by the National Institute 
of Health (NIH) and to create the country’s own 
law on genetic modifications. 1984 was the year 
of the first German in vitro birth and the launch of 
insulin production based on genetic engineering 
(Hampel et al. 2001). 1980 and 1990 saw govern-
ment investment in the development of the bio-
technology sector doubled, since it begun to at-
tract attention as an industry of the future, with a 
foreseeable growth rate of 25%. However, as late 
as in the early 1990s, Germany was considered 
the least biotechnology development-friendly 
country in the Western world (Dohse, Staehler 
2008). The state strategy in support of biotech-
Fig. 2. Number of PCT patent applications in selected countries of the world, 1998–2011
Source: own calculations based on OECD data
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nology development was based on supporting 
SMEs and connecting the industry and univer-
sities while ensuring financial support by banks, 
which assigned part of their capital for high-risk 
investment projects. In addition, biotechnology 
development was stimulated by setting up 17 
Bio Regios, technologically-oriented regions – 
production clusters forming a network of links 
between scientific institutions and academics, 
industry, services, and political and social organ-
isations. Their role was to encourage local entities 
to collaborate in promoting the entrepreneurial 
spirit among academics and scientists, and to as-
sist in setting up biotech start-ups and business-
es. 
The newly created regional formations con-
sisted of both local government and state entities, 
manufacturing and industrial plants as well as 
R&D centres. The structure was different in each 
BioRegio and did not require the involvement of 
all types of entities. In extreme cases, it was com-
posed solely of an R&D centre. Therefore, regions 
differed in terms of their operational structure and 
size. Some were composed of single cities with 
their impact zones, e.g. Freiburg, Jena or Regens-
burg. Others formed a network of neighbouring 
cities, e.g. Braunschweig–Gottingen–Hannover, 
or Heidelberg–Mannheim–Ludwigshafen. On 
the other hand, the Berlin-Brandenburg region 
covered the entire federal state. The differenti-
ation caused a difference in the potential of the 
regions. The most populous Berlin-Brandenburg 
region had a population of 6 million, while Bio-
Regio Jena reported approximately 100,000 in-
habitants. Geographically, the majority of oth-
er regions were located in the core industrial 
districts of Germany: Region Rhein-Main with 
Wiesbaden, Frankfurt, Darmstadt and Mainz, or 
Rhein-Neckar-Dreieck with Heidelberg, Mann-
heim and Ludwigshafen. Only regions such as 
Greifswald-Rostock and Wilhelmshaven-Olden-
burg occupied peripheral areas of the north-east-
ern and north-western parts of Germany. As a 
result of a competition based on the biotechno-
logical competitiveness of regions, three were se-
lected: Munich, Rhineland and Rhein-Neckar, to 
Fig. 3. Number of clinical trials in biotechnology according to the U.P. National Institute of Health
Source: own calculations based on U.P. National Institute of Health data
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receive a public aid of €76.7 billion and serve as 
best-practice cases. The Jena region of the former 
GDR joined the three regions as an example of a 
successful use of biotechnology in the process of 
the economic integration of united Germany. The 
process was to lead regions to achieve specialisa-
tion in developing biotechnology. In 1999, on the 
basis of an operational analysis of the bioregions, 
those which had achieved regional competitive 
advantage were selected. They were clusters in 
Berlin, Hannover and Stuttgart. A total of €50 
million were allocated to these regions by the 
Federal Ministry of Education and Scientific Re-
search (Dohse, Staehler 2008).
As a result of activities taken by the govern-
ment, the number of small and medium-sized 
biotech companies doubled in the late 1990s (Fig. 
4). In 1999, Germany reported the highest num-
ber of start-ups in the life-sciences sector in Eu-
rope. The growth was also attributed to growing 
outsourcing by large pharmaceutical companies, 
with 20% of their research processes delegated 
outside (Adelberger 1999). 
The biotechnological development of Germa-
ny in the discussed period resulted mainly from 
the fact that, from the onset, federal government 
efforts focused on assuring high-quality basic re-
search in biotechnology and its commercial ap-
plication. To this end, public research labs were 
financed by offers of funds, mainly for basic re-
search at universities. As early as 1975, the state 
authorities set up the Organisation for Biotech-
nology Research (GBF) integrating research cen-
tres with nearly 600 scientists. The leading Ger-
man centres were: Max-Delbrueck, the Centre 
for Molecular Medicine (MDC) in Berlin, the GSF 
Research Centre for Environment and Health in 
Munich, and the German Cancer Research Cen-
tre in Heidelberg. From 1997 to 2007, the budgets 
of those institutions, financed both by the federal 
government and regional authorities, went up by 
33% compared with the average growth of 15% 
in other centres (Rammer et al. 2008). 
Next, efforts towards developing biotechnol-
ogy involved the commercialisation of basic re-
search accompanied by the development of en-
trepreneurship in academic circles. The number 
of dedicated biotech firms (dBFs) in Germany 
went up rapidly from 250 in 1997 – the year of the 
first payments under the BioRegio programme – 
to more than 500 in 2002. Biotech companies ap-
peared predominantly in regions which received 
state subsidies. In 2006, 145 out of 494 dBFs were 
located in seven regions selected in competitions 
(BioRegio), while 135 operated in other regions. 
The increase in the number of biotech companies 
in the above-mentioned seven regions occurred 
largely at the initial stage of financing (1998–
2003), when the regions received the highest fi-
nancial support (Häussler, Zademach 2007). The 
biggest chunk of total BioRegio financing (more 
than 60%) went to private companies, most of 
them start-ups. Consequently, approximately 
2/3 of all companies co-financed under the Bio-
Regio programme were set up in 1997 or later, 
i.e. during BioRegio exploitation. In the case of 
other regions, the beneficiaries were mainly pub-
lic institutions (universities, research centres, 
community organisations), while private biotech 
companies received 37% of the total funds. In the 
light of the above, it is hardly surprising that the 
number of dBFs was growing faster in the pro-
moted regions than in other parts of Germany, 
while in other bioregions the growth was com-
parable with the remaining part of the country. 
Similarly, the annual employment growth rate 
from 1998 to 2006 in the seven supported regions 
remained considerably higher (11.8%) than in 
other bioregions (3.3%), while the national aver-
age was 2.4%.
Biotechnological development in Germany 
was initiated chiefly through state support and 
bank loans. Private investment (venture capital, 
VC) in the sector grew as late as the mid–1990s. 
1995 to 2000 saw over a 10–fold increase (from 
Fig. 4. Number of biotech companies in Germany, 1997–
2012
Source: own calculations based on Dohse (2000) and the Internet 
portal biotechnologie.de
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€50 million to nearly €500 million) in the VC val-
ue in biotech companies. Geographically, private 
investment would mainly go to previously cre-
ated regions supported by the state. The average 
number of private venture-capital investments in 
companies formerly co-financed under BioRegio 
was higher by as much as 60% than the average 
VC amount invested in companies without state 
Fig. 5. German biotech clusters in 1996, the distribution of biotech companies (one dot can represent one or more companies) 
and their change 1996–1998
Source: own studies on the basis of Dohse (2000)
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support. This shows that BioRegio financing had 
a considerable impact on attractiveness to pri-
vate investors. Of the seven regions, from 1995 
to 2005, the highest number of investors were 
attracted by Munich (approximately €900 mil-
lion, nearly 37% of the value of total investment 
in the region). In the ranking by VC invested, 
Munich was followed by Rhein-Neckar (Hei-
delberg) (€400 million), Berlin (approximately 
€300 million), and Rhineland (approx. €250 mil-
lion). The observed increase in investment and 
cash flows shows that the regions have external 
openness. The process, leading to the creation of 
links and relations via collaboration, as well as 
relationships and interaction between entities in-
side and outside a cluster, influences the efficien-
cy and contributes to the competitiveness of the 
cluster. Also in the area of science, the selected 
regions received nearly 50% of their total funds 
from the German Science Foundation (Deutsche 
Forschungsgemeinschaft, DFG).
Summing up the first period of biotechnology 
development in Germany, one may say that it oc-
curred mainly in regions which received govern-
ment support, including mostly seven regions: 
Berlin, Munich, Rhineland, Jena, Lower Saxony 
(Niedersachsen), Stuttgart, and Rhein-Neckar. 
Among the regions, Berlin and Bavaria (Bayern) 
Fig. 6. Regional distribution of biotech companies in 2005 and 2013, and per million people
Source: own calculations based on the Internet portal biotechnologie.de
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with Munich were the main poles of biotechnol-
ogy growth. 
In the years that followed, the spatial distribu-
tion of biotechnology centres did not change sig-
nificantly. Most regions reported growth of dBFs 
between 2006 and 2013. The highest number of 
biotech companies were set up in the most bio-
logically developed regions of Germany: Nord-
rhein-Westfalen (35 companies) as well as Bavar-
ia (12), Baden-württemberg (10) and Berlin (9) 
(Fig. 6). However, when compared with 2005, the 
highest average growth in the analysed period 
was recorded in regions below the top companies 
in the German biotechnological ranking: Rhein-
Fig. 7. Change in the number of biotech companies, 2005–2013 (2005=100)
Source: own calculations based on the Internet portal biotechnologie.de
Fig. 8. Biotech companies per 10,000 firms and their structure in 2011
Source: own calculations based on the Internet portal biotechnologie.de
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land-Pfalz reporting the average growth of 29%, 
Mecklenburg-Vorpommern growing at 27%, and 
Hessen at 23%.
Sachens-Ahnalt was the only region report-
ing a drop in the number of biotech companies 
(Fig. 7). In spite of such substantial growth in 
their number outside the leading biotechnolo-
gy centres in Germany, their structure has not 
changed significantly. Invariably, Bavaria hosts 
nearly 20% of the companies, 15% are based in 
Baden-württemberg, and 11% in Berlin. Only 
Nordrhein-Westfallen recorded distinctive 
growth in its share of the total number of biotech 
companies, from 11.5% in 2005 to 16.2% in 2013. 
In other cases, the shares changed only slightly. 
In the category of regions (NUTS 2), Germa-
ny ranks among European leaders with its share 
of biotech companies per 10,000 firms, after the 
British Merseyside region with the MerseyBIO 
cluster (Dorocki, Jastrzębski 2012; Fig. 8). Those 
are largely the urban regions of Brandenburg and 
Bavaria, which overlap with the leading biotech-
nology centres of Germany. In most regions, R&D 
service companies1 prevail, hand in hand with bi-
otech companies operating in the therapeutic and 
1  R&D companies provide supporting services, such as 
product development, analytical services, screening, 
production, as well as R&D services for the biotech-
nological industry. However, some companies may 
both, work on drug development and offer services at 
the same time. In that case, the main field of a compa-
ny’s operation prevails. 
Fig. 9. Average number of patent applications in the regions of Germany, 1990–2010
Source: own calculations based on Eurostat
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diagnostic sector2 (T&D), which illustrates high 
scientific and technological advancement of these 
regions. Other biotech companies, not involved 
in research on treating humans, focus on farm-
ing, cosmetics, environmental protection, food 
technology, industrial biotechnology, naturceutic 
or veterinary problems; they were the least repre-
sented in the structure of most German regions.
The regional distribution of biotechnological 
patents in Germany copies that of the biotechnol-
ogy industry, which confirms the interaction be-
tween research and production. The supremacy of 
large metropolises in developing biotechnologi-
cal innovation is confirmed by the average num-
ber of biotechnological patent applications over 
the years 1990–2010 (Fig. 9) in regions with large 
agglomerations that are simultaneously business, 
commercial and R&D centres. First and foremost, 
this would be the region of Upper Bavaria with 
Munich (the Max Planck Institute for Biochemis-
try), Darmstadt with Frankfurt am Main (the Max 
Planck Institute for Biophysics) and Berlin (the Bi-
otechnology Training Centre). This indicates that 
regions that lead in the rise in the number of pat-
ent applications are those with great human cap-
ital, tertiary education institutions/ universities 
and R&D, as well as high commercial potential al-
lowing direct transfer of innovation to production 
and service companies (Fig. 10). This dependence 
is confirmed by analyses of regional differences in 
human potential in Europe (Borowiec et al. 2009) 
and in economic potential (Rachwał 2013).
The importance of the economic potential for 
developing the biotechnology sector is confirmed 
by the regional distribution of biotech plants and 
R&D centres in Germany. Out of all regions, the 
highest number of biotech institutions is located 
in south-western Germany: Nordrhein-West-
falen (243), Bavaria (229) and Baden-württem-
2  The key task of T&D companies is to use biotech-
nology for discovering and developing innovative 
therapeutic compounds and analysing compounds in 
terms of their applicability in medicine. These com-
panies must have their own R&D departments and 
infrastructure required to develop innovative drugs. 
Their operation focuses on developing innovative 
therapeutic compounds. This category does not in-
clude enterprises which are only drug producers or 
distributors, have no research department of their 
own, and only deal with generic drugs and do not de-
velop innovative therapeutic compounds.
berg (220) as well as Brandenburg with the Berlin 
region (166 jointly) (Fig. 10). The fewest biotech 
institutions can be found in the northern and cen-
tral regions. The regional structure is dominated 
by biotech enterprises and universities/colleges, 
while the share of independent research centres 
is the lowest. Biotech companies (and dedicated 
dBFs in particular) in most cases have their own 
research base, like universities and colleges. In 
terms of distribution, institutions of the R&D 
sector have the highest share in regions with the 
lowest biotechnological potential, which con-
firms that biotechnology develops through the 
commercialisation of science and collaboration 
between industrial sectors and science.
When analysing the distribution of cities with 
biotechnological centres in 2013, one can see that 
they tend to be located in regions set up in the 
late 1990s (BioRegio). Activity in the field of bi-
ology was reported in 219 cities and towns from 
Berlin in the east to Westfallen in the west, and 
from Hessen to Württemberg and Bavaria in the 
south (Fig. 11). In addition, one can see their con-
centrations in the Leipzig-Halle industrial district 
and in large agglomerations such as Hamburg or 
Dresden. There are also some outstanding scien-
tific centres such as Rostock or Freiburg. Berlin 
and Munich stand out among cities for the num-
ber of centres and institutions they host. Gener-
ally, large cities – seats of leading scientific and 
research institutions – dominate, while the share 
of biotech industry institutions is fairly signifi-
cant in smaller towns with a population of 50,000 
or smaller. When analysing the spatial concentra-
tion of the biotechnology sector, its highest con-
centration is found to be related to universities 
and research institutes, while their highest dis-
persion is reported for other biotech companies 
and vocational colleges.
The above shows that biotech plants are locat-
ed mainly in scientific centres. This is confirmed 
by an analysis of the coexistence of biotech insti-
tutions from the manufacturing and R&D sec-
tors. Generally, when analysing both academic 
institutions and labs, the canonical correlation is 
0.818. when identifying elements, note the high-
est correlation of dedicated biotech companies 
and universities (Fig. 12). In addition, the impact 
of the size of a city on the location of biotechnol-
ogy activity, confirmed for universities and dBFs, 
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was analysed. Given the results of the canonical 
correlation obtained in the analysis, the coexist-
ence of dBFs and private research institutes and 
universities in German towns was examined. 
The results show that one can speak of a strong 
interaction between the specialist biotechnology 
industry and universities. This confirms a strong 
link between the basic research stage and the 
stage of production in the biotechnology sector.
In order to identify the leading biotechnology 
centres of Germany, cities were grouped by us-
ing the k-mean method in order to come up with 
the ranking (Fig. 13). Berlin came first. Its cluster 
is made up of the city of Berlin and its 9 satellite 
cities dominated by the capital. This indicates that 
this is actually a single metropolis region. The dis-
trict is dominated by dFBs and universities oper-
ating largely in white (medical) biotechnology. In 
this way, Berlin is the world’s medical research 
centre in the global top 10 biotech clusters of 2011, 
ranking 8th globally and 2nd in Europe after the 
international BioValley cluster. Berlin is the seat 
of important research institutes, including Bio-
techPark Berlin-Buch with the Max Delbrück 
Centre for Molecular Medicine (MDC), the Leib-
niz Institute for Molecular Pharmacology (FMP), 
and the Experimental Clinical and Research Cen-
tre (ECRC).
The Munich region comes next in the ranking. 
Apart from Munich, the region consists of 10 lo-
cations, including Martinsried, an important bio-
technology centre. They form a part of the Bavaria 
bio-cluster. When compared with Berlin, there are 
many research centres in the region apart from 
Fig. 10. Structure of biotechnology centres in the regions of Germany, 2013
Source: own calculations based on the Internet portal biotechnologie.de
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dBFs and universities, which can be the reason 
for the number of biotechnological patents being 
higher here than in Berlin. The Munich Biotech-
nology Cluster is the leader of the centre, which 
also includes the Foundation of Grosshadern Uni-
versity Clinic as part of Ludwig-Maximilians-Uni-
versität (LMU), the Max Planck Institute of Bio-
chemistry in Martinsried, and the Foundation of 
the Gene Centre Munich as one of four centres for 
applied molecular biological research in Germa-
ny. The state BioRegio initiative, coupled with the 
establishment of the Life Science Centre weihen-
stephan of the Technische Universität München 
(TUM) in 2000, has stimulated the development 
of the sector. Both Berlin and Munich are biotech-
nology centres clearly ahead of other centres in 
Germany. Since Munich and Martinsried form 
a bi-polar system, no competitive biotechnology 
centres have developed in their surroundings (Zi-
oło 2003).
Other biotechnology centres in Germany do 
not have one clearly dominant core but are com-
posed of very many locations representing dif-
ferent biotechnology potentials. The centres are 
described as poly-bioclusters. Among the largest 
clusters of this type is the region stretching from 
Marburg in Hessen to Heidelberg in Baden- Würt-
temberg in the south. It forms a longitudinal strip 
of 35 locations. Heidelberg with its Biotechnology 
Cluster Rhine-Neckar – BioRN (the Heidelberg 
Technology Park and the Institute of Pharmacy 
and Molecular Biotechnology at the University 
of Heidelberg) is the centre of the region. Apart 
from research centres, the cluster offers a well-de-
veloped chemical and pharmaceutical industry: 
BASF, Boehringer Ingelheim, Mannheim (now 
Roche) and Merck, which put it on the right track 
to development (Krauss, Stahlecker 2001). Other 
important biotechnology centres are Mainz Bio-
NTech (Biopharmaceutical New Technology) 
and Frankfurt am Mein with its Innovation Cen-
tre for Biotechnology Frankfurt (FIZ). The region 
hosts many other biotechnology scientific centres 
as well as numerous biotechnology and indus-
try collaboration networks. The regions boasts a 
considerable share of biotechnology vocational 
Fig. 11. Distribution of cities and biotech institutions (A), city size structure (B), and concentration (C) of biotech institutions 
in Germany, 2013
Source: own calculations based on the Internet portal biotechnologie.de
 SPATIAL DIVERSITY OF BIOTECHNOLOGY CENTRES IN GERMANY  165
colleges and other biotech companies, which in-
dicates the development of less technologically 
advanced biotech companies. 
The next region is Rhein-Ruhra in Nord rhein-
Westfallen, a region with a long tradition of in-
dustry. Its leading centres with similar biotech-
nology potentials are Bonn, Cologne, Düsseldorf 
and Münster in the north. The region consists of 
35 centres, with their heaviest concentration in the 
Bonn-Düsseldorf strip. It is dominated by univer-
sities and research centres operating mostly in the 
LifeScienceNet Düsseldorf, BioCologne, Der Bio-
Industry, Clusters für Biotechnologie, Bio.NRW, 
and the Bio-Tech-Region OstwestfalenLippe.
Another important biotechnology centre 
in Germany is a region consisting of two cen-
tres: Stuttgart and Tübingen. Its other cities are 
Reutlingen and Esslingen, and the clusters that 
operate here are BioRegio Stern and BioPro 
Baden-Württemberg.
Apart from the above-mentioned centres, there 
are some biotechnology centres of low concentra-
tion, different potentials and small shares in bio-
technology patents in central Germany. The area 
can be considered both a set of individual biotech-
nology centres or as one large centre, and that is 
why it is described as a multi-biocluster region. 
Its key centres are Hannover in Lower Saxony 
with BioRegioN and Göttingen with Georg-Au-
gust-Universität Göttingen, as well as Leipzig (Bio 
City Leipzig) and Halle (Bio Mitteldeutschland) in 
Saxony. The first two are dominated by scientific 
centres, while in Saxony the key role is played by 
biotech companies. Other 25 locations of the re-
gions are seats of biotech companies representing 
low potential for development.
Other centres where biotech institutions are 
located do not form clearly identifiable centres, 
or they offer low biotechnology potential. Only 
Rostock and Freiburg can be referred to as bio-
Fig. 12. Dependence between the location of biotech production and R&D centres in Germany, 2013
Source: own calculations based on the Internet portal biotechnologie.de
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technology centres as such. In the case of Ros-
tock, its biotechnology potential is created largely 
by scientific institutions, including the Universi-
ty of Rostock and the BioCon Valley Mecklen-
burg-Vorpommern. In turn, Freiburg is part of 
the European international BioValley cluster 
made up of such centres as Basel (Switzerland) 
and Strasbourg (France).
Although they form bioregions and have 
large agglomerations with numerous biotechnol-
ogy institutions, north Germany, eastern Hessen 
and Thüringen, and southern Saxony have failed 
to develop strong biotechnology centres. This can 
indicate a competitive advantage of centres locat-
ed in former East Germany, which early received 
the highest financial support. Other factors can 
include cultural aspects connected with the spir-
it of entrepreneurship and social capital, whose 
role in the commercialisation of tasks and setting 
up start-ups cannot be underestimated. Besides, 
as in the case of Lower Saxony, the general eco-
nomic condition, in addition to human capital 
and scientific institutions, seems to have a deci-
sive impact on developing biotechnologies.
Summing up
The spatial distribution of biotechnology cen-
tres in Germany is characterised by heavy con-
centration. The Berlin and Munich agglomera-
tions with their satellite cities are the main poles 
of biotechnology centres development. In other 
cases, biotechnology centres are parts of clusters 
Fig. 13. Biotechnology centres in Germany, 2013
Source: own calculations based on the Internet portal biotechnologie.de
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differing in size and specialisation. The spatial 
proximity of biotech plants, centres and institu-
tions confirms the need for a strong interaction 
of biotech entities. The largest German biotech-
nology centres have developed as a result of 
stimulation by the state and setting up BioRegi-
os, which mainly offer financial support to new 
investment projects. Scientific institutions, pre-
dominantly universities, are the factor which has 
determined the development of German biotech-
nology. They ensure both competitive scientific 
solutions as well as adequately educated staff. 
Another important factor is the level of econom-
ic development. Its growth creates new possible 
interactions between R&D centres and the indus-
try. For this reason, advanced biotechnology de-
velops mostly in large, economically robust and 
vibrant agglomerations and in the traditional in-
dustrial sectors. In the case of the so-called other 
biotech companies, public research institutions 
and higher vocational schools, their distribution 
is less connected with large agglomerations and 
they are characterised by lower spatial concen-
trations of locations. Finally, note that in Germa-
ny the growth of biotechnology has been largely 
stimulated by the state policy, which has created 
biotechnology centres on the basis of the exist-
ing R&D centres and the biotechnology industry 
closely related to them, i.e. a successful combina-
tion of money and ideas.
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